NRXSHealthcare · Biotechnology

NRXS Stock Forecast: NeurAxis, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$6.15

−1.91% on the day

The 2 Wall Street analysts covering NeurAxis, Inc. hold a median 12-month price target of $11 — +78.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 22 Aug 2026 — in the upper half.

Market cap

$77.2M

Ticker Nerd rank

54 / 100

Median analyst target

$11

Analysts covering

Total return, dividends reinvested

−2.4%

−12.3%

YTD

+35.5%

+163.9%

From 52W high

−30.2%

From 52W low

+166.2%

$2.31

$8.81

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

NRXS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NeurAxis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum

Size

Accruals

Growth

Volatility

Issuance

Revisions

Value

Quality

Momentum (92): The shares have been drifting up relative to others.

Quality (28): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NRXS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRXS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $9Median $11High $13

The green dot is the last close — the median target sits +78.9% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
20 Mar 2026	Craig-Hallum	Maintains	Buy	—
22 Dec 2025	Craig-Hallum	Maintains	Buy	—
16 June 2025	Craig-Hallum	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRXS appears on the weeks it earns a place.

Estimates

NRXS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

NeurAxis, Inc. (NRXS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −6.5×
Price / sales: 14.5×
Price / book: 11.4×
EV / EBITDA: −9.1×

Growth & margins

Revenue growth (YoY): 115.7%
Earnings growth (YoY): 79.5%
Gross margin: 86.4%
Operating margin: −110.2%
Net margin: −144.4%

Returns & dividend

Return on equity: −139.8%
Return on assets: −56.2%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NRXS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
NRXSNeurAxis, Inc.	$77.2M	54
GOSSGossamer Bio, Inc.	$75.6M	54
ANVSAnnovis Bio, Inc.	$77.4M	26
TELOTelomir Pharmaceuticals, Inc.	$77.7M	13
SERSerina Therapeutics, Inc.	$72.9M	18
ELTXElicio Therapeutics, Inc.	$79.9M	38
CINGCingulate, Inc.	$80.7M	28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NeurAxis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NRXS news & analysis

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

Zacks Investment Research · 14 Aug 2026positive

NeurAxis reported record second-quarter 2026 revenues, driven by stronger IB-Stim demand, higher pricing, and an improved reimbursement mix that lifted gross margin. Despite the revenue surge, the NRXS stock dipped after the earnings report.

Why it matters — A NRXS watcher would care because the record revenues and higher gross margin signal improved underlying commercial performance for the company's IB-Stim business despite the post-earnings share dip.

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Seeking Alpha published the transcript of NeurAxis, Inc.'s (NRXS) Q2 2026 earnings call, covering the company's quarterly financial results and management discussion.

Why it matters — A NRXS watcher would care because the earnings call transcript provides direct insight into the company's Q2 2026 performance and management's commentary on its operations.

NeurAxis Expands Payer Coverage with New Policies

GlobeNewsWire · 4 Aug 2026positive

NeurAxis announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. The coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.

Why it matters — Expanded payer coverage broadens potential patient access to NeurAxis's IB-Stim treatment in a new region.

NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

GlobeNewsWire · 28 July 2026neutral

NeurAxis announced it will report its second quarter 2026 financial results before market open on Tuesday, August 11, 2026, and will host a conference call at 9:00 am ET that same day to review the results and provide a business update.

Why it matters — Investors monitoring NRXS will gain insight into the company's recent financial performance and operational progress during the quarterly update call.

FAQ

Frequently asked questions about NRXS stock

What is the NRXS stock price forecast for 2026-2027?

The 2 Wall Street analysts covering NeurAxis, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRXS stock a buy right now?

Of the 2 analysts covering NeurAxis, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeurAxis, Inc. 54 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRXS?

As at 22 Aug 2026, NeurAxis, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will NRXS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +78.9% from the last close, and Ticker Nerd's factor model ranks NeurAxis, Inc. 54 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRXS stock forecast for 2030?

No analyst covering NeurAxis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $13 over the next 12 months.

How has NRXS stock performed over the past year?

NeurAxis, Inc. returned +163.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NeurAxis, Inc. do?

Neuraxis Inc. operates as a biotechnology company focused on the development and commercialization of innovative medical solutions aimed at improving neurological health.

What is the latest news on NRXS?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up". NeurAxis reported record second-quarter 2026 revenues, driven by stronger IB-Stim demand, higher pricing, and an improved reimbursement mix that lifted gross margin. Despite the revenue surge, the NRXS stock dipped after the earnings report.

Company

About NeurAxis, Inc.

Neuraxis Inc. operates as a biotechnology company focused on the development and commercialization of innovative medical solutions aimed at improving neurological health. Its core mission is to create breakthrough therapies that address various neurological disorders, a field that holds significant importance given the increasing prevalence of such conditions globally. Neuraxis Inc. leverages cutting-edge research and technology to advance treatments in this critical sector, which impacts a wide array of neurological diseases, including but not limited to, neurodegenerative and neurodevelopmental disorders. The company’s work is pivotal in contributing to the broader healthcare and pharmaceutical industries, with particular emphasis on improving patient outcomes and quality of life. Neuraxis Inc.'s position within the biotech landscape highlights its role in driving forward therapeutic innovations and enhancing the understanding and treatment efficacy within neurology. As the demand for advanced neurological treatments continues to grow, Neuraxis Inc. remains at the forefront, influencing the market dynamics with its research-driven approach.

CEO Mr. Brian Carrico · 24 employees · United States · https://neuraxis.com